Researchers analyzed data from 1,760 patients with multidrug-resistant (MDR) Gram-negative infections. They compared different treatment methods, including colistin monotherapy, colistin-based combinations, and beta-lactam/beta-lactamase inhibitor (BL/BLI) therapies.
The analysis found that BL/BLI therapy was associated with a significant reduction in all-cause mortality compared to colistin monotherapy. Additionally, colistin-based combination therapies showed higher rates of clinical cure and microbiological eradication than colistin used alone. A key safety finding was that BL/BLI-based regimens were linked to a lower risk of nephrotoxicity, which is damage to the kidneys.
It is important to note that the evidence for these findings is of very low certainty. Because the data quality is limited, these results should not be seen as a definitive rule for all patients. Doctors should consider these findings as one part of a larger clinical picture when choosing the best treatment for complex infections.
